Furthermore, EGCG augments the effectiveness of doxorubicin and paclitaxel in overcoming MDR in NSCLC (H1975), human oral epidermal cancer (KB-A1), and lung cancer (H460/PT) cells by inhibiting both the protein function and expression of P-gp [537–539]. Here, PGP is linked to lung carcinoma.